Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Full Access To HCV Drugs Would Save Money Long-Term, Study Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

Restricting coverage to the sickest HCV patients saves individual Medicaid programs money in the short-term, a study by ISPOR finds, but increases costs for Medicare in the longer-term.

Advertisement

Related Content

Gilead Sees Prospects For Declining HCV Revenues To Stabilize

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register